News & Updates

Long-term aspirin use lowers HCC risk in chronic HBV patients
Long-term aspirin use lowers HCC risk in chronic HBV patients
14 May 2022
Oral silymarin reduces chemo-induced hepatotoxicity in breast cancer patients
Oral silymarin reduces chemo-induced hepatotoxicity in breast cancer patients
06 May 2022
Cardiometabolic risk tied to NAFLD
Cardiometabolic risk tied to NAFLD
16 Apr 2022

Cardiometabolic risk factors increase the risk of nonalcoholic fatty liver disease (NAFLD), though such interactions seem to vary between lean and nonlean individuals, a recent study has found.

Cardiometabolic risk tied to NAFLD
16 Apr 2022
Seladelpar safe, effective for primary biliary cholangitis
Seladelpar safe, effective for primary biliary cholangitis
10 Apr 2022

In patients with primary biliary cholangitis, the use of seladelpar, a selective peroxisome proliferator-activated receptor-delta agonist, safely improves biochemical markers of cholestasis and inflammation, reports a new study.

Seladelpar safe, effective for primary biliary cholangitis
10 Apr 2022
Hepatitis B virus treatment rates still low among eligible patients
Hepatitis B virus treatment rates still low among eligible patients
10 Apr 2022
Immune-related adverse events portend better prognosis in ICI-treated hepatocellular carcinoma
Immune-related adverse events portend better prognosis in ICI-treated hepatocellular carcinoma
08 Mar 2022 byJairia Dela Cruz

Among advanced hepatocellular carcinoma patients being treated with immune checkpoint inhibitors (ICIs), the occurrence of multisystem and more severe immune-related adverse events is a favourable signal, being associated with survival advantage, according to a Singapore study.

Immune-related adverse events portend better prognosis in ICI-treated hepatocellular carcinoma
08 Mar 2022